Ninofloxacin malate capsule, a new drug of Zhejiang medicine, has passed the CDE expert review meeting

On October 13, the company confirmed that the drug had passed the expert review meeting, along with the API, "the follow-up is waiting for on-site inspection" This means that the important obstacles to the approval of nanofloxacin have been removed and the review process has taken a big step forward The company's Securities Department responded that the drug was indeed discussed in September, but did not know the results of the expert discussion "After that, there are still many review processes, and there is still time to be approved." Nanofloxacin was purchased from Taijing biology in Taiwan by Zhejiang medicine and declared for production in July last year As a new non fluoroquinolones drug, ninofloxacin has been highly concerned by the market since it was approved Zhejiang Pharmaceutical previously announced that as a high-end product of quinolones in the future, nanofloxacin will form a benign complementary advantage with the company's existing quinolones and antibiotic resistant products, and enrich the company's high-end antibiotic product group.